Company: SNY
Filing Date: 2025-07-10
Form Type: SC TO-T/A
Source: 0001193125-25-157299
Chunk: 3

Company: Sanofi
Filing Date: 2025-07-10
Form: SC TO-T/A
Chunk 3
---
el Office (“ FCO”) and either the FCO has declared clearance of the transaction or certain waiting periods have expired. The parties submitted a notification to the FCO on June 10, 2025. German merger control clearance was received on June 30, 2025.”

| (4) | The subsection entitled “Italy Foreign Direct Investment Compliance” in Section 16 –                                                                                                         
 “Certain Legal Matters; Regulatory Approvals” is amended and supplemented by deleting the last two sentences of the paragraph and adding the following sentence at the end of the paragraph: |

“The parties submitted a notification on June 9, 2025. On June 25, 2025, the Presidency of the Council of Ministers in Italy confirmed that the Merger does not fall within the scope of Law Decree No. 21/2012.”

| (5) | Section 16 — “Certain Legal Matters; Regulatory Approvals” is hereby amended and                                      
 supplemented by adding the following to the end of such Section after the subsection captioned “State Takeover Laws”: |

“ Legal Proceedings Relating to the Tender Offer. Between June 24, 2025 and July 10, 2025, two complaints were filed in the Supreme Court of the State of New York, County of New York (“ Sup. Ct. N.Y. Cnty.”) by purported stockholders of the Company: Williams v. Blueprint Medicines Corp., et al., No. 653805/2025 (Sup. Ct. N.Y. Cnty., filed June 24, 2025); and Phillips v. Blueprint Medicines Corp., et al., No. 653820/2025 (Sup. Ct. N.Y. Cnty., filed June 25, 2025) (collectively, the “ Merger Actions”). The Merger Actions name the Company and the members of the board of directors of the Company as defendants. The Merger Actions generally allege that the Schedule 14D-9is materially incomplete and misleading by allegedly failing to disclose purportedly material information, and assert claims for negligent misrepresentation and concealment, and negligence under New York law against the Company and the Company Board. The Merger Actions seek, among other things, an injunction enjoining the consummation of the Transactions, rescission of the Transactions if consummated, costs of the action, including attorneys’ fees and experts’ fees and expenses, an award of damages, and any other relief the court may deem just and proper.